[8-K] Exelixis Inc Reports Material Event
On August 29, 2025, Exelixis, Inc. announced an internal leadership change: Dana T. Aftab, Ph.D., currently the company鈥檚 Executive Vice President, Discovery and Translational Research and Chief Scientific Officer, was appointed Executive Vice President, Research and Development. The filing states information about Dr. Aftab鈥檚 background, compensation arrangements, and any related-party transactions is incorporated by reference from the company鈥檚 definitive proxy statement on Schedule 14A filed April 16, 2025. Effective the same day, Amy C. Peterson, M.D., concluded her service as Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer, and is entitled to payments under the company鈥檚 Change in Control and Severance Benefit Plan, as amended, and applicable law.
Il 29 agosto 2025, Exelixis, Inc. ha comunicato una modifica interna alla leadership: Dana T. Aftab, Ph.D., attualmente Vice President Esecutiva, Discovery and Translational Research e Chief Scientific Officer dell鈥檃zienda, 猫 stata nominata Executive Vice President, Research and Development. Nel deposito si dichiara che le informazioni sul background della Dr.ssa Aftab, sugli accordi di compenso e su eventuali operazioni con parti correlate sono incorporate per riferimento nella dichiarazione definitiva di procura su Schedule 14A presentata il 16 aprile 2025. Con effetto nello stesso giorno, Amy C. Peterson, M.D., ha concluso il suo incarico come Executive Vice President, Product Development and Medical Affairs e Chief Medical Officer, ed ha diritto ai pagamenti previsti dal Change in Control and Severance Benefit Plan dell鈥檃zienda, cos矛 come modificato, e dalla normativa applicabile.
El 29 de agosto de 2025, Exelixis, Inc. anunci贸 un cambio interno en la direcci贸n: Dana T. Aftab, Ph.D., actualmente Vicepresidenta Ejecutiva de Discovery and Translational Research y Chief Scientific Officer de la compa帽铆a, fue nombrada Executive Vice President, Research and Development. La presentaci贸n indica que la informaci贸n sobre la trayectoria de la Dra. Aftab, los acuerdos de compensaci贸n y cualquier transacci贸n con partes relacionadas se incorpora por referencia desde la declaraci贸n definitiva de poder en el Schedule 14A presentada el 16 de abril de 2025. Con efecto el mismo d铆a, Amy C. Peterson, M.D., concluy贸 su servicio como Executive Vice President, Product Development and Medical Affairs y Chief Medical Officer, y tiene derecho a los pagos seg煤n el Change in Control and Severance Benefit Plan de la compa帽铆a, seg煤n enmendado, y la ley aplicable.
2025雲� 8鞗� 29鞚�, Exelixis, Inc.電� 雮措秬 毽崝鞁� 氤�霃欖潉 氚滍憸頄堨姷雼堧嫟. 順勳灛 須岇偓鞚� Executive Vice President, Discovery and Translational Research 氚� Chief Scientific Officer鞚� Dana T. Aftab 氚曥偓(Ph.D.)臧� Executive Vice President, Research and Development搿� 鞛勲獏霅橃棃鞀惦媹雼�. 鞝滌稖 靹滊鞐愲姅 Aftab 氚曥偓鞚� 瓴诫牓, 氤挫儊 甏�霠� 鞎届爼 氚� 甏�霠瀽 瓯半灅鞐� 甏�頃� 鞝曤炒臧� 2025雲� 4鞗� 16鞚� 鞝滌稖霅� Schedule 14A鞚� 頇曥爼 鞙勳瀯鞛�(definitive proxy statement)鞐� 鞚橅暣 彀胳“搿� 韽暔霅橃柎 鞛堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 臧欖潃 雮犽秬搿� Amy C. Peterson 氚曥偓(M.D.)電� Executive Vice President, Product Development and Medical Affairs 氚� Chief Medical Officer搿滌劀鞚� 歆侂毳� 毵堧毽枅鞙茧┌, 須岇偓鞚� 氤�瓴� 韱奠牅 氚� 頃搓碃 旮夓棳 鞝滊弰(Change in Control and Severance Benefit Plan, 靾橃爼霅� 雽�搿�)鞕� 甏�霠� 氩曤鞐� 霐半ジ 歆�旮夓潉 氚涭潉 鞛愱博鞚� 鞛堨姷雼堧嫟.
Le 29 ao没t 2025, Exelixis, Inc. a annonc茅 un changement de direction interne聽: Dana T. Aftab, Ph.D., actuellement Executive Vice President, Discovery and Translational Research et Chief Scientific Officer de la soci茅t茅, a 茅t茅 nomm茅e Executive Vice President, Research and Development. Le d茅p么t indique que les informations concernant le parcours de la Dre Aftab, les accords de r茅mun茅ration et les 茅ventuelles transactions avec des parties li茅es sont incorpor茅es par renvoi 脿 la d茅claration d茅finitive de procuration sur le Schedule 14A d茅pos茅e le 16 avril 2025. 脌 la m锚me date, Amy C. Peterson, M.D., a mis fin 脿 ses fonctions d鈥橢xecutive Vice President, Product Development and Medical Affairs et de Chief Medical Officer, et elle a droit aux paiements pr茅vus par le Change in Control and Severance Benefit Plan de la soci茅t茅, tel que modifi茅, ainsi que par la loi applicable.
Am 29. August 2025 gab Exelixis, Inc. eine interne F眉hrungs盲nderung bekannt: Dana T. Aftab, Ph.D., derzeit Executive Vice President, Discovery and Translational Research und Chief Scientific Officer des Unternehmens, wurde zur Executive Vice President, Research and Development ernannt. In der Einreichung wird angegeben, dass Informationen zu Dr. Aftabs Werdegang, Verg眉tungsregelungen und etwaigen Transaktionen mit nahestehenden Parteien durch Bezugnahme in die definitive Vollmachtsstellungnahme auf Schedule 14A vom 16. April 2025 einbezogen sind. Mit Wirkung zum selben Tag beendete Amy C. Peterson, M.D., ihren Dienst als Executive Vice President, Product Development and Medical Affairs und Chief Medical Officer und hat Anspruch auf Zahlungen gem盲脽 dem Change in Control and Severance Benefit Plan des Unternehmens, in der ge盲nderten Fassung, sowie nach anwendbarem Recht.
- Leadership continuity through an internal promotion of Dana T. Aftab, Ph.D., which preserves institutional knowledge in R&D
- Consistent disclosure by incorporating background and compensation details from the company鈥檚 April 16, 2025 Schedule 14A proxy statement
- Departure of the Chief Medical Officer, Amy C. Peterson, which removes an established medical affairs leader from the executive team
- Severance payments to the departing CMO under the Change in Control and Severance Benefit Plan are required, though amounts are not disclosed in this filing
Insights
TL;DR: Routine executive succession with internal promotion and a departing C-suite officer receiving contractual severance protections.
The appointment of Dr. Aftab from an existing senior scientific role to head R&D signals continuity in leadership rather than an external strategic shift, and the disclosure references prior proxy filing details for background and compensation, preserving disclosure consistency. The departure of the Chief Medical Officer, Amy Peterson, triggers contractual severance under the company鈥檚 Change in Control and Severance Benefit Plan, which the company explicitly notes without quantifying amounts in this filing.
TL;DR: Internal promotion likely sustains ongoing research programs; CMO departure noted but specifics of clinical impact are not disclosed.
Promoting the existing Chief Scientific Officer to lead Research and Development suggests management intends to keep scientific strategy intact. The filing does not disclose any program-level changes, clinical delays, or personnel impacts beyond the executive transition. No financial amounts or operational effects on development programs are provided; background and compensation details are deferred to the April 16, 2025 proxy statement.
Il 29 agosto 2025, Exelixis, Inc. ha comunicato una modifica interna alla leadership: Dana T. Aftab, Ph.D., attualmente Vice President Esecutiva, Discovery and Translational Research e Chief Scientific Officer dell鈥檃zienda, 猫 stata nominata Executive Vice President, Research and Development. Nel deposito si dichiara che le informazioni sul background della Dr.ssa Aftab, sugli accordi di compenso e su eventuali operazioni con parti correlate sono incorporate per riferimento nella dichiarazione definitiva di procura su Schedule 14A presentata il 16 aprile 2025. Con effetto nello stesso giorno, Amy C. Peterson, M.D., ha concluso il suo incarico come Executive Vice President, Product Development and Medical Affairs e Chief Medical Officer, ed ha diritto ai pagamenti previsti dal Change in Control and Severance Benefit Plan dell鈥檃zienda, cos矛 come modificato, e dalla normativa applicabile.
El 29 de agosto de 2025, Exelixis, Inc. anunci贸 un cambio interno en la direcci贸n: Dana T. Aftab, Ph.D., actualmente Vicepresidenta Ejecutiva de Discovery and Translational Research y Chief Scientific Officer de la compa帽铆a, fue nombrada Executive Vice President, Research and Development. La presentaci贸n indica que la informaci贸n sobre la trayectoria de la Dra. Aftab, los acuerdos de compensaci贸n y cualquier transacci贸n con partes relacionadas se incorpora por referencia desde la declaraci贸n definitiva de poder en el Schedule 14A presentada el 16 de abril de 2025. Con efecto el mismo d铆a, Amy C. Peterson, M.D., concluy贸 su servicio como Executive Vice President, Product Development and Medical Affairs y Chief Medical Officer, y tiene derecho a los pagos seg煤n el Change in Control and Severance Benefit Plan de la compa帽铆a, seg煤n enmendado, y la ley aplicable.
2025雲� 8鞗� 29鞚�, Exelixis, Inc.電� 雮措秬 毽崝鞁� 氤�霃欖潉 氚滍憸頄堨姷雼堧嫟. 順勳灛 須岇偓鞚� Executive Vice President, Discovery and Translational Research 氚� Chief Scientific Officer鞚� Dana T. Aftab 氚曥偓(Ph.D.)臧� Executive Vice President, Research and Development搿� 鞛勲獏霅橃棃鞀惦媹雼�. 鞝滌稖 靹滊鞐愲姅 Aftab 氚曥偓鞚� 瓴诫牓, 氤挫儊 甏�霠� 鞎届爼 氚� 甏�霠瀽 瓯半灅鞐� 甏�頃� 鞝曤炒臧� 2025雲� 4鞗� 16鞚� 鞝滌稖霅� Schedule 14A鞚� 頇曥爼 鞙勳瀯鞛�(definitive proxy statement)鞐� 鞚橅暣 彀胳“搿� 韽暔霅橃柎 鞛堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 臧欖潃 雮犽秬搿� Amy C. Peterson 氚曥偓(M.D.)電� Executive Vice President, Product Development and Medical Affairs 氚� Chief Medical Officer搿滌劀鞚� 歆侂毳� 毵堧毽枅鞙茧┌, 須岇偓鞚� 氤�瓴� 韱奠牅 氚� 頃搓碃 旮夓棳 鞝滊弰(Change in Control and Severance Benefit Plan, 靾橃爼霅� 雽�搿�)鞕� 甏�霠� 氩曤鞐� 霐半ジ 歆�旮夓潉 氚涭潉 鞛愱博鞚� 鞛堨姷雼堧嫟.
Le 29 ao没t 2025, Exelixis, Inc. a annonc茅 un changement de direction interne聽: Dana T. Aftab, Ph.D., actuellement Executive Vice President, Discovery and Translational Research et Chief Scientific Officer de la soci茅t茅, a 茅t茅 nomm茅e Executive Vice President, Research and Development. Le d茅p么t indique que les informations concernant le parcours de la Dre Aftab, les accords de r茅mun茅ration et les 茅ventuelles transactions avec des parties li茅es sont incorpor茅es par renvoi 脿 la d茅claration d茅finitive de procuration sur le Schedule 14A d茅pos茅e le 16 avril 2025. 脌 la m锚me date, Amy C. Peterson, M.D., a mis fin 脿 ses fonctions d鈥橢xecutive Vice President, Product Development and Medical Affairs et de Chief Medical Officer, et elle a droit aux paiements pr茅vus par le Change in Control and Severance Benefit Plan de la soci茅t茅, tel que modifi茅, ainsi que par la loi applicable.
Am 29. August 2025 gab Exelixis, Inc. eine interne F眉hrungs盲nderung bekannt: Dana T. Aftab, Ph.D., derzeit Executive Vice President, Discovery and Translational Research und Chief Scientific Officer des Unternehmens, wurde zur Executive Vice President, Research and Development ernannt. In der Einreichung wird angegeben, dass Informationen zu Dr. Aftabs Werdegang, Verg眉tungsregelungen und etwaigen Transaktionen mit nahestehenden Parteien durch Bezugnahme in die definitive Vollmachtsstellungnahme auf Schedule 14A vom 16. April 2025 einbezogen sind. Mit Wirkung zum selben Tag beendete Amy C. Peterson, M.D., ihren Dienst als Executive Vice President, Product Development and Medical Affairs und Chief Medical Officer und hat Anspruch auf Zahlungen gem盲脽 dem Change in Control and Severance Benefit Plan des Unternehmens, in der ge盲nderten Fassung, sowie nach anwendbarem Recht.
| FORM | |||||
 | ||
| (Exact name of registrant as specified in its charter) | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
EXELIXIS, INC. | |||||||||||
| August 29, 2025 | /s/ Jeffrey J. Hessekiel | ||||||||||
| Date | Jeffrey J. Hessekiel | ||||||||||
| Executive Vice President and General Counsel | |||||||||||
Source:
FAQ
What executive changes did Exelixis (EXEL) announce on August 29, 2025?
When did the leadership changes at Exelixis take effect?
Where can I find details about Dr. Aftab鈥檚 background and compensation?
Will Amy Peterson receive any payments upon departure?
Does the filing disclose financial impacts from these executive changes?
